title: Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin.
authors.forename: Firouzé
authors.initials: F
authors.lastname: Bani-Sadr
authors.forename: Isabelle
authors.initials: I
authors.lastname: Goderel
authors.forename: Nathanael
authors.initials: N
authors.lastname: Lapidus
authors.forename: Henda
authors.initials: H
authors.lastname: Driss
authors.forename: Anne
authors.initials: A
authors.lastname: Simon
authors.forename: Eric
authors.initials: E
authors.lastname: Rosenthal
authors.forename: Patrice
authors.initials: P
authors.lastname: Morand
authors.forename: Françoise
authors.initials: F
authors.lastname: Lunel-Fabiani
authors.forename: Stanislas
authors.initials: S
authors.lastname: Pol
authors.forename: Patrice
authors.initials: P
authors.lastname: Cacoub
authors.forename: Christian
authors.initials: C
authors.lastname: Perronne
authors.forename: Fabrice
authors.initials: F
authors.lastname: Carrat
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects*
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin